Table 3.
Association between clinical characteristics of patients with non-small-cell lung cancer and polymorphism of locus rs727088
| Characteristics | Patients, n | Genotype n (%)
|
P-value | Allele n (%)
|
P-value | OR (95% CI) | |||
|---|---|---|---|---|---|---|---|---|---|
| AA | AG | GG | A | G | |||||
| Sex | |||||||||
| Female | 86 | 34 (39.5) | 43 (50.0) | 9 (10.5) | 0.677 | 111 (64.5) | 61 (35.5) | 0.640 | 1.09 (0.76–1.58) |
| Male | 216 | 75 (34.7) | 120 (55.6) | 21 (9.7) | 270 (65.5) | 162 (37.5) | |||
| Age | |||||||||
| ≤60 years | 170 | 63 (37.1) | 91 (53.5) | 16 (9.4) | 0.895 | 217 (63.8) | 123 (36.2) | 0.667 | 1.08 (0.77–1.50) |
| >60 years | 132 | 46 (34.8) | 72 (54.5) | 14 (10.6) | 164 (62.1) | 100 (37.9) | |||
| Histological type | |||||||||
| ADC | 1,381 | 49 (35.5) | 75 (54.3) | 14 (10.1) | 173 (62.7) | 103 (37.3) | |||
| SCC | 138 | 47 (34.1) | 77 (55.8) | 14 (10.1) | 0.967 | 171 (62.0) | 105 (38.0) | 0.861 | 1.03 (0.73–1.46) |
| Others | 26 | 13 (50.0) | 11 (42.3) | 2 (7.7) | 0.376 | 37 (71.2) | 15 (28.8) | 0.364 | 0.68 (0.36–1.30) |
| Differentiation | |||||||||
| Poor | 204 | 72 (35.3) | 111 (54.4) | 21 (10.3) | 0.898 | 255 (62.5) | 153 (37.5) | 0.670 | 0.93 (0.65–1.32) |
| Moderate–well | 98 | 37 (37.8) | 52 (53.1) | 9 (9.2) | 126 (64.3) | 70 (35.7) | |||
| Tumor size | |||||||||
| T1 | 34 | 16 (47.1) | 16 (47.1) | 2 (5.9) | 48 (70.6) | 20 (29.4) | |||
| T2 | 192 | 72 (37.5) | 101 (52.6) | 19 (9.9) | 0.509 | 245 (63.8) | 139 (36.2) | 0.280 | 1.36 (0.78–2.39) |
| T3 | 51 | 15 (29.4) | 28 (54.9) | 8 (15.7) | 0.161 | 58 (56.9) | 44 (43.1) | 0.070 | 1.82 (0.95–3.51) |
| T4 | 25 | 6 (24.0) | 18 (72.0) | 1 (4.0) | 0.156 | 30 (60.0) | 20 (40.0) | 0.230 | 1.60 (0.74–3.45) |
| Lymph node | |||||||||
| N0 | 157 | 55 (35.0) | 87 (55.4) | 15 (9.6) | 197 (62.7) | 117 (37.3) | |||
| N1 | 107 | 48 (44.9) | 51 (47.7) | 8 (7.5) | 0.270 | 147 (68.7) | 67 (31.3) | 0.167 | 0.77 (0.53–1.12) |
| N2 | 38 | 6 (15.8) | 25 (65.8) | 7 (18.4) | 0.042a | 37 (48.7) | 39 (51.3) | 0.024a | 1.78 (1.08–2.95) |
| Metastasis | |||||||||
| M0 | 285 | 103 (36.1) | 156 (54.7) | 26 (9.1) | 0.142 | 362 (63.5) | 208 (36.5) | 0.371 | 1.37 (0.68–2.76) |
| M1 | 17 | 6 (35.3) | 7 (41.2) | 4 (23.5) | 19 (55.9) | 15 (44.1) | |||
| Clinical stage | |||||||||
| I + II | 223 | 90 (40.4) | 113 (50.7) | 20 (9.0) | 0.033a | 193 (55.8) | 153 (44.2) | 0.986 | 0.99 (0.68–1.46) |
| III + IV | 79 | 19 (24.1) | 50 (63.3) | 10 (12.7) | 88 (55.7) | 70 (44.3) | |||
Notes:
a
Statistically significant.
Abbreviations: ADC, adenocarcinoma; SCC, squamous cell carcinoma; OR, odds ratio; CI, confidence interval.